2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2016

9:00AM-11:00AM: Abstract Number: 496

Impact of Anti-Citrullinated Protein Antibody and/or Rheumatoid Factor on Rheumatoid Arthritis Manifestations and Outcomes

Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

9:00AM-11:00AM: Abstract Number: 232

Impact of Gout Flare Prophylaxis and Urate-Lowering Therapy on Endothelial Function, Smooth Muscle Responsiveness and Markers of Inflammation: Results of a Prospective Observational Pilot Study

Metabolic and Crystal Arthropathies - Poster I: Clinical Practice

9:00AM-11:00AM: Abstract Number: 720

Impact of HLA-B27 on Patient Profile and Treatment Response in As Patients Treated with Anti-TNF in Canadian Real-World

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster I: Axial and Peripheral Spondyloarthritis – Clinical Aspects, Imaging and Treatment

9:00AM-11:00AM: Abstract Number: 30

Impact of Interstitial Lung Disease on Mortality of Patients with Rheumatoid Arthritis

Epidemiology and Public Health - Poster I

9:00AM-11:00AM: Abstract Number: 119

Impact of Socioeconomic Status on Disease Outcomes in Japanese Patients with Rheumatoid Arthritis Under the Japanese National Insurance System

Healthcare Disparities in Rheumatology - Poster I

9:00AM-11:00AM: Abstract Number: 735

Impact of Time Since Diagnosis, Age, and Number of Prior Non-Steroidal Anti-Inflammatory Drugs on Response to Adalimumab (HUMIRA) in Patients with Ankylosing Spondylitis

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster I: Axial and Peripheral Spondyloarthritis – Clinical Aspects, Imaging and Treatment

9:00AM-11:00AM: Abstract Number: 186

Impact of TLR Stimulation on Cytokine Production in Macrophage Subsets: TLR2 Stimulation Impairs Anti-Inflammatory Activity of M2 Macrophages

Innate Immunity and Rheumatic Disease - Poster I

9:00AM-11:00AM: Abstract Number: 90

Impacts of Anti-TNF Treatment on Improvement in Work Place and Household Productivity in Patients with Psoriatic Arthritis

Health Services Research - Poster I

9:00AM-11:00AM: Abstract Number: 819

Impaired Adiponectin Signaling in SSc Contributes to Myofibroblast Differentiation and Organ Fibrosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics - Poster I

9:00AM-11:00AM: Abstract Number: 474

Impaired Cognition Is Linked to Brain Depletion in Brain-Derived Neurotrophic Factor Levels in a Rat Model of Rheumatoid Arthritis

Rheumatoid Arthritis – Animal Models - Poster I

9:00AM-11:00AM: Abstract Number: 271

Impaired Satellite Cell Activation and Myofiber Transition during Skeletal Muscle Regeneration in Patients with Polymyositis and Dermatomyositis

Muscle Biology, Myositis and Myopathies - Poster I: Basic/Translational

9:00AM-11:00AM: Abstract Number: 530

Importance of Functional and Utility Evaluation on Disease Activity Level in Rheumatoid Arthritis: Interrelations and Predictive Value

Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

9:00AM-11:00AM: Abstract Number: 444

Improvement in Knee Arthrocentesis Via Constant Compression

Quality Measures and Quality of Care - Poster I

9:00AM-11:00AM: Abstract Number: 107

Improvement of Quality and Cost-Effectiveness of Rheumatology Care By Creating Long-Term Alliances with Pharmaceutical Companies

Health Services Research - ARHP Poster

9:00AM-11:00AM: Abstract Number: 441

Improving Care and Avoiding Errors. Can Our Patients Recall Their Medications and Create an Accurate Medication List?

Quality Measures and Quality of Care - Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].